The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Open accessAbstract
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets. Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approximately 25% of all AML cases). FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approximately 7–10% of all cases), is uncertain. Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum. This so-called clonal evolution, together with the identification of FLT3-ITD as a negative prognostic marker, serves to highlight the importance of FLT3-ITD testing at diagnosis and again at relapse. Earlier identification of FLT3 mutations will help provide a better understanding of the patient’s disease and enable targeted treatment that may help patients achieve longer and more durable remissions. First-generation FLT3 inhibitors developed for clinical use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities associated with off-target effects. Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational. This review focuses on the pathological and prognostic role of FLT3 mutations in AML, clinical classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Self-citationClonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 735
Self-citationStone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V., Bixby, D., Blum, W., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 654
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Self-citationWhitman, S. P., Archer, K. J., Lin, F., Baldus, C. D., Becknell, B., Carlson, B. D., Carroll, A. J., Mrózek, K., Vardiman, J., George, S. L., et al. (2001) · PubMed · Cited by 633
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Self-citationSpectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9678 · Cited by 504
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30416-3 · Cited by 490
Self-citationBacher, U., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2008) · Blood · doi:10.1182/blood-2007-05-091215 · Cited by 411
Schlenk, R. F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., Held, G., Brossart, P., Lübbert, M., Salih, H. R., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578070 · Cited by 404
Self-citationRöllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Self-citationRavandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480228 · Cited by 381
Self-citationServe, H., Krug, U., Wagner, R., Sauerland, M. C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4990 · Cited by 313
Kottaridis, P. D., Gale, R. E., Langabeer, S. E., Frew, M. E., Bowen, D. T., & Linch, D. C. (2002) · Blood · doi:10.1182/blood-2002-02-0420 · Cited by 307
Shih, L.-Y., Huang, C.-F., Wu, J.-H., Lin, T.-L., Dunn, P., Wang, P.-N., Kuo, M.-C., Lai, C.-L., & Hsu, H.-C. (2002) · Blood · doi:10.1182/blood-2002-01-0195 · Cited by 306
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lee, L. Y., Hernandez, D., Rajkhowa, T., Smith, S. C., Raman, J. R., Nguyen, B., Small, D., & Levis, M. (2017) · Blood · doi:10.1182/blood-2016-10-745133 · Cited by 280
Self-citationGaidzik, V. I., Teleanu, V, Papaemmanuil, E., Weber, D., Paschka, P., Hahn, J., Wallrabenstein, T., Kolbinger, B., Köhne, C. H., Horst, H. A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.126 · Cited by 279
Self-citationClonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Krönke, J., Bullinger, L., Teleanu, V., Tschürtz, F., Gaidzik, V. I., Kühn, M. W. M., Rücker, F. G., Holzmann, K., Paschka, P., Kapp-Schwörer, S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-479188 · Cited by 273
Self-citationGrafone, T., Palmisano, M., Nicci, C., & Storti, S. (2012) · Oncology Reviews · doi:10.4081/oncol.2012.e8 · Cited by 273
Stone, R. M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C. A., Ehninger, G., Cortes, J., Kantarjian, H. M., DeAngelo, D. J., Huntsman-Labed, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.115 · Cited by 272
Heidel, F., Solem, F. K., Breitenbuecher, F., Lipka, D. B., Kasper, S., Thiede, M. H., Brandts, C., Serve, H., Roesel, J., Giles, F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2469 · Cited by 270
Kayser, S., Schlenk, R. F., Londono, M. C., Breitenbuecher, F., Wittke, K., Du, J., Groner, S., Späth, D., Krauter, J., Ganser, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209999 · Cited by 269
Self-citationCortes, J., Perl, A. E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30240-7 · Cited by 266
Self-citationFLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Self-citationAcquired copy number alterations in adult acute myeloid leukemia genomes
Walter, M. J., Payton, J. E., Ries, R. E., Shannon, W. D., Deshmukh, H., Zhao, Y., Baty, J., Heath, S., Westervelt, P., Watson, M. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903091106 · Cited by 246
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Levis, M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.220 · Cited by 243
Self-citationFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Pratz, K. W., Sato, T., Murphy, K. M., Stine, A., Rajkhowa, T., & Levis, M. (2010) · Blood · doi:10.1182/blood-2009-09-242859 · Cited by 242
Self-citationStirewalt, D. L., Kopecky, K. J., Meshinchi, S., Engel, J. H., Pogosova-Agadjanyan, E. L., Linsley, J., Slovak, M. L., Willman, C. L., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2005-08-3453 · Cited by 239
Chen, Y.-B., Li, S., Lane, A. A., Connolly, C., Del Rio, C., Valles, B., Curtis, M., Ballen, K., Cutler, C., Dey, B. R., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.09.007 · Cited by 236
Self-citationPiloto, O., Wright, M., Brown, P., Kim, K.-T., Levis, M., & Small, D. (2007) · Blood · doi:10.1182/blood-2006-05-023804 · Cited by 204
Self-citationPhase I study of sorafenib in patients with refractory or relapsed acute leukemias
Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J. J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030452 · Cited by 202
Chao, Q., Sprankle, K. G., Grotzfeld, R. M., Lai, A. G., Carter, T. A., Velasco, A. M., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., James, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9007533 · Cited by 198
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
Cloos, J., Goemans, B. F., Hess, C. J., van Oostveen, J. W., Waisfisz, Q., Corthals, S., de Lange, D., Boeckx, N., Hählen, K., Reinhardt, D., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404246 · Cited by 179
Pratz, K. W., Cortes, J., Roboz, G. J., Rao, N., Arowojolu, O., Stine, A., Shiotsu, Y., Shudo, A., Akinaga, S., Small, D., et al. (2009) · Blood · doi:10.1182/blood-2008-09-177030 · Cited by 179
Self-citationGerman-Austrian AML Study Group (AMLSG), Nagel, G., Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3150-3 · Cited by 172
Self-citationSecondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
Self-citationThe evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Wander, S. A., Levis, M. J., & Fathi, A. T. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532123 · Cited by 166
Self-citationFGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Traer, E., Martinez, J., Javidi-Sharifi, N., Agarwal, A., Dunlap, J., English, I., Kovacsovics, T., Tyner, J. W., Wong, M., & Druker, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3569 · Cited by 165
D. Kottaridis, P., Gale, R. E., & Linch, D. C. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04500.x · Cited by 158
Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G. M., Goldberg, S. L., Perl, A. E., Marie, J., Martinelli, G., Kantarjian, H. M., et al. (2018) · Blood · doi:10.1182/blood-2018-01-821629 · Cited by 156
Self-citationKnapper, S., Russell, N. H., Gilkes, A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730648 · Cited by 150
Self-citationYang, X., Sexauer, A. N., & Levis, M. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12599 · Cited by 140
Self-citationSandmaier, B. M., Khaled, S. K., Oran, B., Gammon, G. M., Trone, D., & Frankfurt, O. (2017) · American Journal of Hematology · doi:10.1002/ajh.24959 · Cited by 134
Kampa-Schittenhelm, K. M., Heinrich, M. C., Akmut, F., Döhner, H., Döhner, K., & Schittenhelm, M. M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-19 · Cited by 125
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
Linch, D. C., Hills, R. K., Burnett, A. K., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554667 · Cited by 122
Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia
Grimwade, D. J., & Mrózek, K. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.018 · Cited by 120
Wattad, M. A., Weber, D., Döhner, K., Krauter, J., Gaidzik, V. I., Paschka, P., Heuser, M., Thol, F. R., Kindler, T., Lübbert, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.23 · Cited by 116
Self-citationPort, M., Böttcher, M., Thol, F. R., Ganser, A., Schlenk, R. F., Wasem, J., Neumann, A., & Pouryamout, L. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2072-6 · Cited by 108
Self-citationvon Bubnoff, N. C. C., Engh, R. A., Åberg, E., Sänger, J., Peschel, C., & Duyster, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2923 · Cited by 104
Cortes, J. E., Kantarjian, H. M., Kadia, T. M., Borthakur, G. M., Konopleva, M. Y., Garcia‐Manero, G., Daver, N. G., Pemmaraju, N., Jabbour, E. J., Estrov, Z. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7008 · Cited by 102
Self-citationThe importance of FLT3 mutational analysis in acute myeloid leukemia
Patnaik, M. M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1399312 · Cited by 99
Altman, J. K., Foran, J. M., Pratz, K. W., Trone, D., Cortes, J. E., & Tallman, M. S. (2017) · American Journal of Hematology · doi:10.1002/ajh.24974 · Cited by 98
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
Dutreix, C., Munarini, F., Lorenzo, S., Roesel, J. L., & Wang, Y. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2287-6 · Cited by 90
Ravandi, F., Yi, C. A., Cortes, J. E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.54 · Cited by 87
Ho, A. D., Schetelig, J., Bochtler, T., Schaich, M. A., Schäfer‐Eckart, K., Hänel, M., Rösler, W., Einsele, H., Kaufmann, M., Serve, H. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.10.023 · Cited by 86
Oran, B., Cortes, J. E., Beitinjaneh, A., Chen, H.-C., Lima, M. J. G. D., Patel, K. P., Ravandi, F., Wang, X., Brandt, M., Andersson, B. S., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.03.027 · Cited by 86
Swaminathan, M., Kantarjian, H. M., Daver, N. G., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.723.723 · Cited by 73
Self-citationAMLSG, A. F. T. G.-A., Schlenk, R. F., Frech, P., Weber, D., Brossart, P., Horst, H., Kraemer, D. M., Held, G., Ringhoffer, M., Burchardt, A. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.22 · Cited by 69
Self-citationPonatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
Shah, N. P., Talpaz, M., Deininger, M. W., Mauro, M. J., Flinn, I. W., Bixby, D. L., Lustgarten, S., Gozgit, J. M., Clackson, T., Turner, C. D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12382 · Cited by 61
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients
Warren, M., Luthra, R., Yin, C. C., Ravandi, F., Cortes, J. E., Kantarjian, H. M., Medeiros, L. J., & Zuo, Z. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.88 · Cited by 61
McCormick, S. R., McCormick, M. J., Grutkoski, P. S., Ducker, G. S., Banerji, N., Higgins, R. R., Mendiola, J. R., & Reinartz, J. J. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0292-oa.1 · Cited by 58
Nazha, A., Cortes, J. E., Faderl, S., Pierce, S. A., Daver, N., Kadia, T. M., Borthakur, G., Luthra, R., Kantarjian, H. M., & Ravandi, F. (2012) · Haematologica · doi:10.3324/haematol.2012.062638 · Cited by 51
Self-citationGunawardane, R. N., Nepomuceno, R. R., Rooks, A. M., Hunt, J. P., Ricono, J. M., Belli, B., & Armstrong, R. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0305 · Cited by 48
Schlenk, R. F., Döhner, K., Salih, H. R., Kündgen, A., Fiedler, W., Salwender, H.-J., Westermann, J., Götze, K. S. S., Horst, H., Wulf, G. G., et al. (2015) · Blood · doi:10.1182/blood.v126.23.322.322 · Cited by 40
Self-citationDisseminated Herpes simplex in Untreated Multiple Myeloma
Deresinski, S. C., & Stevens, D. A. (2009) · Oncology · doi:10.1159/000224970 · Cited by 39
Grunwald, M. R., Tseng, L., Lin, M., Pratz, K. W., Eshleman, J. R., Levis, M. J., & Gocke, C. D. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.08.015 · Cited by 35
Self-citationBadar, T., Kantarjian, H. M., Nogueras‐González, G. M., Borthakur, G. M., Garcia‐Manero, G., Andreeff, M., Konopleva, M. Y., Kadia, T. M., Daver, N. G., Wierda, W. G., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24140 · Cited by 26
Self-citationHills, R. K., Gammon, G. M., Trone, D., & Burnett, A. K. (2015) · Blood · doi:10.1182/blood.v126.23.2557.2557 · Cited by 13
George, T. I., Tworek, J. A., Thomas, N., Fatheree, L. A., Souers, R. J., Nakhleh, R. E., & Arber, D. A. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0398-cp · Cited by 13
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Erba, H. P., Montesinos, P., Kim, H.-J., Patkowska, E., Vrhovac, R., Žák, P., Wang, P.-N., Mitov, T., Hanyok, J., Kamel, Y. M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00464-6 · Cited by 418
Self-citationThe leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Metadata
- Authors
- Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J.
- Venue
- Leukemia
- Published
- 2019-01-16
- Volume
- 33
- Issue
- 2
- Pages
- 299-312
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2909346948
- Cited by
- 1,075
- References
- 82
- FWCI
- 79.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.